Lipocine Inc.

Lipocine Inc. (NASDAQ: LPCN) is a biopharmaceutical company focused on developing innovative oral drug delivery solutions for molecules that have historically been difficult to deliver through conventional formulations. The company leverages its proprietary lipidic delivery technology platform to create orally bioavailable treatments across multiple therapeutic areas including neurological and psychiatric central nervous system disorders, liver disease, and hormone supplementation.

The company's most advanced commercial product is TLANDO, an oral testosterone replacement therapy approved by the FDA in March 2022. TLANDO has been licensed to multiple partners for commercialization in specific territories: Verity Pharmaceuticals for the United States and Canada, SPC Korea Limited for South Korea, Pharmalink for Gulf Cooperation Council countries, and Aché for Brazil. Lipocine retains development and commercialization rights outside these licensed territories and continues to explore additional partnership opportunities for TLANDO expansion.

Lipocine's clinical development pipeline focuses on neuroactive steroids targeting significant unmet medical needs. The lead candidate is LPCN 1154, an oral formulation of brexanolone for postpartum depression, which completed enrollment in a Phase 3 pivotal trial as of February 2026 with data expected in April 2026. Additional pipeline candidates include LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, and LPCN 2401 for improved body composition in obesity management as an adjunct to GLP-1 therapies.

The company also maintains earlier-stage assets including LPCN 1148 for decompensated cirrhosis management, which demonstrated positive Phase 2 results, and LPCN 1107, a potential first oral hydroxy progesterone caproate product for prevention of preterm birth that has received orphan drug designation.

Lipocine's proprietary technology platform creates optimal dispersed phases in the gastrointestinal environment to improve drug absorption, enabling improved bioavailability, reduced dosing requirements, faster absorption, and reduced food effects compared to conventional formulations. The company is classified as a smaller reporting company and is not a well-known seasoned issuer.